Core Viewpoint - Yuan Dong Bio's stock price increased by 5% to 62.15 CNY per share, with a total market capitalization of 10.971 billion CNY as of the report date [1] Company Overview - Chengdu Yuan Dong Bio-Pharmaceutical Co., Ltd. was established on June 1, 2009, and went public on September 2, 2020. The company specializes in the research, development, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Yuan Dong Bio, with the Guotou Ruijin Healthcare Mixed A Fund (000523) holding 98,300 shares, accounting for 2.96% of the fund's net value, making it the seventh-largest holding [2] - The fund has achieved a year-to-date return of 41.79%, ranking 1532 out of 8172 in its category, and a one-year return of 58.96%, ranking 2416 out of 7980 [2] Fund Manager Information - The fund manager of Guotou Ruijin Healthcare Mixed A Fund is Liu Zexu, who has been in the position for 2 years and 9 days. The total asset size of the fund is 198 million CNY, with the best return during his tenure being 39.66% and the worst being 24.38% [3]
苑东生物股价涨5%,国投瑞银基金旗下1只基金重仓,持有9.83万股浮盈赚取29.11万元